Oversold

CDNA

Valuation41/ 100
Cash flow & growth64/ 100
Upside potential49/ 100
Risk potential55/ 100

CDNA's valuation appears fair, fundamentals are somewhat mixed, while forward estimates point to improving growth and profitability, though analyst coverage is limited.

Score change since last week

The score fell 4 points, mainly due to valuation and price changes. Price rose 2.2%, from $49.79 to $50.88. Reported EPS was unchanged, so the higher price reduced valuation support.

Valuation and price changes subtracted 3.1 points. The comparison uses the same available inputs on both dates. Displayed changes are rounded to whole points.

Valuation

Historical cheapness: current PE is 24.3× versus the full-history median of 14.8× shown in the valuation table, producing 39.3/100. Positive weekly observations receive equal weight; lower past EPS alone does not disqualify them.

Outlook-adjusted valuation: 41.2/100. The model applies a 27.7% earnings-growth assumption and a 10% annual return hurdle, with positive credit limited by evidence coverage and confidence.

Forward price scenarios use recent PE history separately. Recent history has a separately weighted median of 14.9× (18-month half-life). A reliable earnings-based price target is unavailable. A return to the full-history median is not assumed.

Cash flow & growth

Business trends are mixed. Over the past year: revenue +34.4%, earnings +103.1%, operating margin -14.2 percentage points. Free cash flow is 18.6% of revenue. The business score is 64.2/100. Growth, margins and cash generation drive the score. Missing or older data receives less weight.

Favorable scenario

Weaker business results limit upside support. Price history provides the reference because earnings are difficult to compare.

The calculation starts with the stock’s typical weekly price movements, adjusted for business performance and outlook. Unusually large jumps have less influence. The result is 52.5% upside, or about $76.65.

This is a scenario based on our model, not a forecast or probability.

Downside scenario

Historical price swings are the main risk driver, even without a sharp profit decline.

The stock’s historical price swings drive this figure; the separate operating stress is 31.5%. Price history and operating stress provide the reference because comparable earnings do not support a future PE target. Operating stress reflects revenue, earnings, margins, outlook and relevant debt exposure. The larger stress gives 54.9% downside, or about $22.67, with a 15% minimum.

This is a scenario based on our model, not a forecast or probability.

CDNA vs Historical averages

MetricCurrentAverageRelative
PE24x15x58% higher
PE percentile9849100% higher
EPS$2.07-$0.90$2.97 higher
FCF$85M-$9.3M+$94.3M
Loading historical comparisons…

CDNA’s earnings are above their historical averages, while its earnings multiple is higher.

CDNA Forward outlook

MetricOutlook
Forward valuationStrongly improving
Forward earningsStrong growth
Forward revenueGrowth
Forward profitabilityStrongly expanding
Analyst coverageLimited
Estimate dispersionTight

CDNA’s outlook is generally improving, though analyst coverage is limited.

CDNA PE Valuation

Loading pe valuation table…

This table applies CDNA's historical price-to-earnings (PE) landmarks to current earnings. The implied prices are valuation scenarios, not price forecasts or targets.

CDNA Earnings Per Share

Loading earnings per share…

This chart tracks CDNA's trailing twelve-month diluted earnings per share, calculated from four consecutive reported quarters to reduce seasonal noise.

CDNA Quarterly Revenue

Loading quarterly revenue…

This chart tracks CDNA's quarterly revenue over time and shows how sales are changing from year to year.

CDNA Free Cash Flow

Loading free cash flow…

This chart tracks CDNA's free cash flow over time, showing whether the business is consistently generating cash after operating costs and capital spending.

CDNA Total Shares

Loading shares over time…

This chart tracks changes in CDNA's diluted share count. A rising count can dilute existing owners, while a falling count often reflects share repurchases.

CDNA Net Leverage

Loading net leverage…

Quarterly Net Leverage uses the last 12 months of EBITDA. A falling multiple generally indicates less debt relative to earnings capacity. Negative values mean net cash; missing data or nonpositive LTM EBITDA are N/A. The table shows each period’s Net Leverage and status.

CDNA PE vs Healthcare Sector

Loading pe vs sector average…

This chart compares CDNA's price-to-earnings (PE) ratio with the Healthcare sector average. A discount or premium can reflect differences in expected growth, profitability, or risk.

CDNA Weekly Price

Loading weekly price…

This chart uses CDNA's weekly closing prices to show the longer-term trend. The lower panes show weekly RSI and Stochastic momentum.

CDNA Weekly Moving Averages

Loading weekly moving averages…

This chart compares CDNA's 8, 20, 50, 100, and 200-week moving averages from 2020 onward. Shorter averages react faster to price changes, while longer averages show the broader trend.

CDNA Yearly ROI

Loading yearly ROI…

Each line starts at 0% using the year’s first dependable weekly close and tracks the return through December, or through the latest available week for the current year.